Recent Articles
Skin substitutes: Understanding product differences
November/December 2016 Vol. 5 No. 6Author: Myra Varnado, BS, RN, CWOCN
Skin substitutes (also called tissuebased products and dermal replacements) are a boon to chronic wound . . .
Read More
Lymphedema and lipedema: What every wound care clinician should know
July/August 2016 Vol. 5 No. 4Author: Heather Hettrick, PT, PhD, CWS, CLT, CLWT
Imagine you have a health condition that affects your life every day. Then imagine being . . .
Read More
Clinician Resources
July/August 2016 Vol. 5 No. 4Wound patient’s bill of rights
The Association for Advancement of Wound Care has developed . . .
Practicing emotional intelligence may help reduce lateral violence
July/August 2016 Vol. 5 No. 4Author: Tara Slagle, MSN, BSN, RN
It’s been a stressful day at work—nothing new. One confused patient pulled off . . .
Read More
Understanding NPUAP’s updates to pressure ulcer terminology and staging
July/August 2016 Vol. 5 No. 4Author: Jeri Lundgren, BSN, RN, PHN, CWS, CWCN
On April 13, 2016, the National Pressure Ulcer Advisory Panel (NPUAP) announced changes in pressure . . .
Read More
Preparing the wound bed: Basic strategies, novel methods
July/August 2016 Vol. 5 No. 4Author: Kulbir Dhillon, NP, WCC
The goal of wound-bed preparation is to create a stable, well-vascularized environment that . . .
Read More
Who can perform sharp wound debridement?
July/August 2016 Vol. 5 No. 4Author: Bill Richlen PT, WCC, DWC, and Denise Richlen, PT, WCC
Nurses and therapists often wonder if their license permits them to perform sharp wound debridement . . .
Read More
Balancing the wheels of life
July/August 2016 Vol. 5 No. 4Author: Tracey Long, PhD, MS, MSN, RN, CDE, CNE, CHUC, CCRN
Have you ever ridden a bicycle with a wobbly wheel? The ride isn’t smooth . . .
Read MoreQuiz Time
Which statement about hyperglycemia and mortality in patients receiving nutritional support is correct?
a. Compared to parenteral nutrition (PN), general nutrition (EN) increases hyperglycemia risk nearly twofold.
b. Compared to EN, PN increases hyperglycemia risk nearly twofold.
c. Patients whose blood glucose (BG) level stays above 220 mg/dL during PN therapy have an increased risk of death.
d. Patients whose blood glucose (BG) level stays above 220 mg/dL during PN therapy have a decreased risk of death.
Correct answer: b. Experts estimate that up to 30% of patients receiving EN and more than 50% of those receiving PN develop hyperglycemia, defined as a BG level above 200 mg/ dL. Compared to EN, PN increases hyperglycemia risk nearly twofold, even when caloric intake is similar. One study found inadequate glucose control both before and during nutrition therapy predicted a higher mortality risk.
Learn more by reading “Supplemental nutrition in hospitalized patients with diabetes“
More Award-Winning Content from HealthCom Media
